Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study
Leyi Lin(Walter Reed Army Institute of Research), Alexander C. Schmidt(GlaxoSmithKline (United States)), Heather Friberg(Walter Reed Army Institute of Research), Stephen J. Thomas(Walter Reed Army Institute of Research), Kirsten E. Lyke(University of Maryland, Baltimore), Kenneth H. Eckels(Walter Reed Army Institute of Research), Robert Paris(GlaxoSmithKline (United States)), Richard G. Jarman(Walter Reed Army Institute of Research), Rafael De La Barrera(Walter Reed Army Institute of Research), David W. Vaughn(Armed Forces Research Institute of Medical Science), Michael Koren(Jacksonville University), Paul B. Keiser(Walter Reed Army Institute of Research), Monica A. McArthur(University of Maryland, Baltimore), Philippe Moris(GlaxoSmithKline (Belgium)), Edith Lepine(GlaxoSmithKline (United States)), Jeffrey R. Currier(Walter Reed Army Institute of Research)
Cited by 17
Related Papers
Neurological manifestations of dengue infection
|The Lancet|2000|637
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
|New England Journal of Medicine|2015|390